TABLE 1

Baseline demographic and clinical characteristics of patients with coronavirus disease 2019 (COVID-19) and healthy volunteers

Patients with COVID-19Healthy volunteers
Subjects n2510
Baseline demographics
Age years64.0 (53.0–75.0)35.0 (22.5–44.0)
Sex
 Female7 (28.0)8 (80.0)
 Male18 (72.0)2 (20.0)
BMI kg·m−228.50 (25.70–31.40)23.86 (22.77–25.89)
Smoking history
 Current smoker1 (4.0)0
 Ex-smoker9 (36.0)1 (10.0)
Patients with COVID-19 (n=25)
Baseline clinical variables
FiO2 at proning0.32 (0.28–0.36)
ABGn=10
 pH7.43 (7.40–7.47)
PaO2 kPa8.00 (7.83–9.03)
PaCO2 kPa4.50 (3.98–4.60)
 Lactate mmol·L−11.70 (1.50–2.10)
FiO20.28 (0.22–0.33)
Inflammatory markersn=25
 WCC (109·L−1)7.90 (6.00–11.10)
 CRP mg·L−177.00 (40.00–141.00)
COVID-19 status
 SARS-CoV-2 PCR positiven=25
 Symptom onset to admission (days)9.0 (3.0–11.0)
 Admission to prone (days)2.0 (1.0–3.0)
 Radiographic severity score5 (4–7)
COVID-19 therapeutic regimen
 Dexamethasone only10 (40.0)
 Dexamethasone+Baricitinib2 (8.0)
 Dexamethasone+Dapagliflozin+Ambrisentan3 (12.0)
 Dexamethasone+EDP1815#1 (4.0)
 Dexamethasone+Ravulizumab2 (8.0)
 Dexamethasone+Remdesivir4 (16.0)
 Dexamethasone+Tocilizumab1 (4.0)
Comorbidities
Respiratory
 Asthma5 (20.0)
 COPD2 (8.0)
 Interstitial lung disease1 (4.0)
 Pulmonary tuberculosis1 (4.0)
Cardiovascular
 Atrial fibrillation2 (8.0)
 Dilated cardiomyopathy1 (4.0)
 Hypercholesterolaemia1 (4.0)
 Hypertension8 (32.0)
 Ischaemic heart disease3 (12.0)
 Peripheral vascular disease1 (4.0)
Other significant
 Connective tissue disease2 (8.0)
 Chronic kidney disease2 (8.0)
 Haematological malignancy1 (4.0)
 Hypothyroidism2 (8.0)
 Osteoarthritis2 (8.0)
 Polymyalgia rheumatica2 (8.0)
 Raynaud's disease1 (4.0)
 Rheumatoid arthritis1 (4.0)
 Type II diabetes mellitus4 (16.0)
Outcomes
 Death1 (4.0)
 Intubation and ventilation1 (4.0)
 Noninvasive ventilation1 (4.0)
 Discharge24 (96)
 Time from proning to discharge (days)7 (4–10.5)

Data are n (%) or median (IQR). Radiographic severity score: semi-quantitative score indicating extent of radiographic changes with a maximum score of 8. BMI: body mass index; FiO2: fractional concentration of oxygen in inspired air at point of proning; ABG: arterial blood gas; PaO2: arterial partial pressure of oxygen; PaCO2: arterial partial pressure of carbon dioxide; WCC: white cell count; CRP: C-reactive protein; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; NA: not applicable. #: EDP1815 is an investigational immune modulator used as part of the TACTIC-E Trial: ClinicalTrials.gov Identifier: NCT04393246.